Given the evidence for its efficacy in this study, its clinical uses for hypertension, renal and liver disease, and the fact that other ACE inhibitors have extended rodent lifespan, follow‐up studies are warranted to establish replicability and if, replicable, optimal dosage. This evidence concerns the gene ACE and liver disorder.